News

Ortivus AB (publ) quarterly report for the period April – June 2021

Ortivus develop healthcare solutions for the future and establishes new strategic partnerships

Highlights April – June 2021

  • Ortivus has entered into a strategic partnership with EMD s.r.o. based in Slovakia. EMD is a well-established provider of medical equipment and digital solutions for prehospital care in Slovakia, the Czech Republic, Hungary and Poland.
  • Mobimed Unity – the first news is released on our new development of one total solution with expanded functionality, new measuring unit and also Mobimed Pocket – an app for smartphones. We create even better functionality for healthcare.
  • Ortivus has recruited Jörgen Petersen as new Service & Support manager and as a member of Ortivus' management team.

April – June 2021

  • Profit after tax was 3.2 (6.9) MSEK
  •  The gross margin rose to 48.9 (28.5)% during the second quarter compared to corresponding period last year.
  • Net sales amounted to 23.6 (40.2) MSEK. Sales during the second quarter of 2020 consisted largely of one-time deliveries to customers in the UK. This means that the periods are not directly comparable.
  • Operating cash flow amounted to 0.4 (5.1) MSEK
  • Earnings per share after tax and before and after dilution amounted to 0.07 (0.15)

January – June 2021

  • Profit after tax was 4.8 (7.9) MSEK
  • The gross margin rose to 49.5 (33.8)% during the first half of the year compared to 2020.
  • Net sales amounted to 47.1 (60.4) MSEK. During the first half of 2020, sales consisted largely of one-time deliveries, which means that the periods are not directly comparable.
  • Operating cash flow amounted to 5.5 (8.3) MSEK
  • Earnings per share after tax and before and after dilution amounted to 0.11 (0.18) SEK
Amount in KSEK Apr-Jun, 2021 Apr-Jun, 2020 Jan-Jun, 2021 Jan-Jun, 2020 Jan-Dec, 2020
Net sales 23.6 40.2 47.1 60.4 107.5
Gross margin, % 48.9% 28.6% 49.5% 33.8% 19.5%
Operating profit 3.2 6.9 4.8 7.9 11.4
Operating margin, % 13.4% 17.1% 10.4% 13.2% 10.6%
EBITDA 3.5 7.5 5.5 9.4 13.9